NEW YORK (GenomeWeb) – Veritas Genetics said today it is creating an R&D center in China to develop genetic products targeting the Asian population. 

The new center will be headquartered in Hangzhou and led by Managing Director Jonathan Zhao; Vice President of Global Clinical and Regulatory Affairs Lei Li; and Vice President of China R&D Min Wang. 

Veritas, which is based in Boston, said that with the new center it is carrying out its mission to "make disease prevention through genetic screening products accessible globally." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.